Expertise in
1
conditions

Mario E. Beiner

Tel Aviv, TA, IL 
Expertise in
1
conditions
Tel Aviv, TA, IL 

Overview

Mario Beiner practices practicing medicine in Tel Aviv, Israel.

Mr. Beiner is highly rated in 1 condition, according to our data. His clinical expertise encompasses Ovarian Cancer, Endometrial Cancer, Menopause, and Salpingo-Oophorectomy.

He is actively involved in clinical research, co-authoring 46 peer reviewed articles and participating in 2 clinical trials.

Gender

Male

Locations

Tel Aviv, TA, Israel
Other Locations
Kfar Saba, M, Israel
Ramat Gan, TA 52621, Israel
Tel Litwinsky, TA, Israel

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

MIRASOL: A Randomized, Open-label, Phase 3 Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression
MIRASOL: A Randomized, Open-label, Phase 3 Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression
Enrollment Status: Completed
Publish Date: August 27, 2025
Intervention Type: Drug
Study Drugs: Mirvetuximab Soravtansine, Paclitaxel, Topotecan, Pegylated liposomal doxorubicin
Study Phase: Phase 3
SORAYA: A Phase 3, Single Arm Study of Mirvetuximab Soravtansine in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression
SORAYA: A Phase 3, Single Arm Study of Mirvetuximab Soravtansine in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression
Enrollment Status: Completed
Publish Date: August 07, 2024
Intervention Type: Drug
Study Drug: Mirvetuximab Soravtansine
Study Phase: Phase 3
View 1 Less Clinical Trial

46 Total Publications

DIO3 associates with sorting nexins and endosomal trafficking networks in ovarian cancer.
DIO3 associates with sorting nexins and endosomal trafficking networks in ovarian cancer.
Journal: Cellular oncology (Dordrecht, Netherlands)
Published: March 03, 2026

Frequently Asked Questions about Mario E. Beiner

Is Mario E. Beiner a top-rated expert for Ovarian Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Mario E. Beiner is classified as an Advanced expert for Ovarian Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Mario E. Beiner participate in research or clinical trials?

Yes. Mario E. Beiner has published 46 articles and abstracts on conditions like Ovarian Cancer. You can view a list of Mario E. Beiner's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Beiner's expertise for a condition
ConditionClose
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile